Ifenprodil
Ifenprodil is a polyamine-antagonistic drug that is primarily used in the treatment of neurological disorders. It is a non-competitive NMDA receptor antagonist, specifically targeting the NR2B subunit. Ifenprodil was first synthesized in the 1970s by the French pharmaceutical company Sanofi.
Pharmacology[edit]
Ifenprodil works by inhibiting the activity of NMDA receptors, which are a type of ionotropic glutamate receptor. These receptors play a crucial role in the transmission of electrical signals in the brain, and their overactivation can lead to neurotoxicity. Ifenprodil selectively blocks the NR2B subunit of the NMDA receptor, which is thought to reduce the risk of side effects associated with non-selective NMDA receptor antagonists.
Clinical Uses[edit]
Ifenprodil is used in the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and ischemic stroke. It is also being investigated for its potential use in the treatment of opioid addiction and depression.
Side Effects[edit]
Common side effects of Ifenprodil include dizziness, nausea, and headache. In rare cases, it can cause more serious side effects such as hallucinations, seizures, and hypotension.
Research[edit]
Research into the potential uses of Ifenprodil is ongoing. Recent studies have suggested that it may have potential as a treatment for chronic pain, schizophrenia, and certain types of cancer.
See Also[edit]
